Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | The pathophysiology of chronic GvHD: current understanding and unanswered questions

Ernst Holler • 19 Apr 2024
EBMT 2024
General Ruxolitinib

Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany, provides insights into the pathophysiology of chronic graft-versus-host disease (GvHD). Early dysfunction of B- and T-cells, along with the role of follicular reticular cells and the ROCK pathway, underscores its complexity. Ruxolitinib shows promise in mitigating Tc17-induced fibrosis. However, unresolved questions remain concerning organ specificity and biomarker identification for chronic GvHD. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

SAB MaatPharma, Lyon, Pharmabiome, Zürich, Medac GmbH, Novartis GmbH; Speakers Bureau, Sanofi, Neovii.

More from Ernst Holler

16:41
The relationship between the gut microbiome and GvHD
Ernst Holler • 19 Apr 2024
2:39
Pathophysiology of GvHD
Ernst Holler • 21 Mar 2022
4:34
Modulation of the microbiota for the treatment of GvHD
Ernst Holler • 21 Mar 2022
4:02
The benefits of GvHD risk stratification
Ernst Holler • 21 Mar 2022

Related Videos

4:09
Veno-occlusive disease as a post-transplant complication of HSCT
Mohamad Mohty • 17 Apr 2024
1:56
Addressing access inequality in CAR-T therapies
Francesca Del Bufalo • 15 Apr 2024
1:34
The future role of AI models in hematology and the need for high-quality data sets
Thomas Coats • 29 Apr 2024
6:38
Key papers in cardio-oncology from 2023 of relevance to hematologists
Alexander Lyon • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals